Needham Maintains Buy on Mereo BioPharma Group, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has maintained a Buy rating on Mereo BioPharma Group (NASDAQ:MREO) and increased the price target from $5 to $6.
March 28, 2024 | 10:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum reaffirmed a Buy rating on Mereo BioPharma Group and raised the price target from $5 to $6.
The increase in price target by a reputable analyst like Gil Blum suggests a positive outlook on Mereo BioPharma Group's stock. Such endorsements often lead to increased investor confidence and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100